James D. Chambers

1.8k total citations
90 papers, 1.2k citations indexed

About

James D. Chambers is a scholar working on Economics and Econometrics, General Health Professions and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, James D. Chambers has authored 90 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Economics and Econometrics, 20 papers in General Health Professions and 16 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in James D. Chambers's work include Health Systems, Economic Evaluations, Quality of Life (62 papers), Pharmaceutical Economics and Policy (36 papers) and Healthcare Policy and Management (20 papers). James D. Chambers is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (62 papers), Pharmaceutical Economics and Policy (36 papers) and Healthcare Policy and Management (20 papers). James D. Chambers collaborates with scholars based in United States, United Kingdom and Canada. James D. Chambers's co-authors include Peter J. Neumann, Joshua T. Cohen, Teja Thorat, Martin Buxton, David D. Kim, Elle Pope, Michael Belkin, Neal R. Barshes, Françoise Simon and Lisa M. Meckley and has published in prestigious journals such as New England Journal of Medicine, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

James D. Chambers

84 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James D. Chambers United States 22 671 205 148 132 118 90 1.2k
Catherine Copley‐Merriman United States 22 469 0.7× 207 1.0× 95 0.6× 145 1.1× 202 1.7× 68 1.7k
Pengxiang Li United States 21 558 0.8× 209 1.0× 53 0.4× 83 0.6× 87 0.7× 70 1.4k
Diana Brixner United States 10 461 0.7× 194 0.9× 65 0.4× 79 0.6× 96 0.8× 37 977
Isao Kamae Japan 20 273 0.4× 110 0.5× 40 0.3× 152 1.2× 82 0.7× 69 1.6k
Ateesha F. Mohamed United States 23 540 0.8× 194 0.9× 77 0.5× 85 0.6× 200 1.7× 66 1.3k
Jörg Ruof Germany 21 401 0.6× 160 0.8× 85 0.6× 103 0.8× 39 0.3× 67 1.4k
Joel Wallace United States 10 254 0.4× 157 0.8× 116 0.8× 76 0.6× 111 0.9× 18 803
Anthony J. Hatswell United Kingdom 17 338 0.5× 80 0.4× 68 0.5× 54 0.4× 204 1.7× 65 826
Jonathan Tosh United Kingdom 17 540 0.8× 243 1.2× 47 0.3× 52 0.4× 86 0.7× 41 1.3k
Ágnes Benedict United States 18 418 0.6× 88 0.4× 78 0.5× 99 0.8× 283 2.4× 57 1.2k

Countries citing papers authored by James D. Chambers

Since Specialization
Citations

This map shows the geographic impact of James D. Chambers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James D. Chambers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James D. Chambers more than expected).

Fields of papers citing papers by James D. Chambers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James D. Chambers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James D. Chambers. The network helps show where James D. Chambers may publish in the future.

Co-authorship network of co-authors of James D. Chambers

This figure shows the co-authorship network connecting the top 25 collaborators of James D. Chambers. A scholar is included among the top collaborators of James D. Chambers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James D. Chambers. James D. Chambers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gibson, Brian, et al.. (2024). Optimal Surgical Approaches for Incidentally Discovered Ruptured Mucinous Appendiceal Neoplasms. Cureus. 16(10). e70808–e70808.
2.
Beinfeld, Molly T., et al.. (2024). Biosimilar underutilization alone does not foretell a broken biologics market. Health Affairs Scholar. 2(7). qxae090–qxae090. 1 indexed citations
3.
Chambers, James D., et al.. (2023). Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration–expedited programs. Journal of Managed Care & Specialty Pharmacy. 29(5). 472–479. 2 indexed citations
4.
Kauf, Teresa L., et al.. (2023). Specialty drug coverage varies between health plans’ medical and pharmacy benefit policies. Journal of Managed Care & Specialty Pharmacy. 29(6). 607–613. 1 indexed citations
5.
Chambers, James D., et al.. (2023). Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions. Journal of Managed Care & Specialty Pharmacy. 29(3). 257–264. 2 indexed citations
6.
Li, Chang, et al.. (2023). Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans. BioDrugs. 37(4). 531–540. 7 indexed citations
7.
Engmann, Natalie J., et al.. (2022). Patients’ access to rare neuromuscular disease therapies varies across US private insurers. Orphanet Journal of Rare Diseases. 17(1). 36–36. 18 indexed citations
8.
Chambers, James D., et al.. (2021). PNS48 Do US Commercial Health Plans Cite ICER Reports in Their Specialty Drug Coverage Policies? an Empirical Analysis. Value in Health. 24. S181–S181. 2 indexed citations
9.
Chambers, James D., et al.. (2021). Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?. PharmacoEconomics. 40(2). 225–232. 7 indexed citations
10.
Kaufman, Howard L., Michael B. Atkins, Prasun Subedi, et al.. (2019). The promise of Immuno-oncology: implications for defining the value of cancer treatment. Journal for ImmunoTherapy of Cancer. 7(1). 129–129. 75 indexed citations
11.
Chambers, James D., et al.. (2017). A Review of Empirical Analyses of Disinvestment Initiatives. Value in Health. 20(7). 909–918. 30 indexed citations
12.
Chambers, James D., et al.. (2017). A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures. Value in Health. 21(4). 400–406. 3 indexed citations
13.
Chambers, James D., Pallavi Rane, & Peter J. Neumann. (2016). The impact of formulary drug exclusion policies on patients and healthcare costs.. PubMed. 22(8). 524–31. 7 indexed citations
14.
Chambers, James D., et al.. (2016). Mapping US commercial payers' coverage policies for medical interventions.. PubMed. 22(9). e323–8. 9 indexed citations
15.
Thorat, Teja, et al.. (2016). Qaly Gains in Cancer Compared with Chronic Diseases. Value in Health. 19(3). A9–A10. 2 indexed citations
16.
Leopold, Christine, James D. Chambers, & Anita K. Wagner. (2015). Thirty Years of Media Coverage on High Drug Prices in the United States—A Never-Ending Story or a Time for Change?. Value in Health. 19(1). 14–16. 4 indexed citations
17.
Sandberg, Eileen A., Thomas F. O’Donnell, James D. Chambers, et al.. (2015). RR19. A Cost-Effective Analysis of Current Strategies for Managing Venous Leg Ulcers. Journal of Vascular Surgery. 61(6). 197S–197S. 1 indexed citations
18.
Chambers, James D., et al.. (2015). Fast-Tracking Innovation: A Scorecard for The Fda’s Expedited Review Process. Value in Health. 18(7). A517–A517. 2 indexed citations
19.
Chambers, James D., Huseyin Naci, Olivier J. Wouters, et al.. (2015). An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic Review. PLoS ONE. 10(4). e0121715–e0121715. 27 indexed citations
20.
Barshes, Neal R., James D. Chambers, Scott B. Cantor, Joshua T. Cohen, & Michael Belkin. (2012). A primer on cost-effectiveness analyses for vascular surgeons. Journal of Vascular Surgery. 55(6). 1794–1800. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Copley‐Merriman Breakdown of academic impact, for papers by Pengxiang Li Breakdown of academic impact, for papers by Diana Brixner Breakdown of academic impact, for papers by Isao Kamae Breakdown of academic impact, for papers by Ateesha F. Mohamed Breakdown of academic impact, for papers by Jörg Ruof Breakdown of academic impact, for papers by Joel Wallace Breakdown of academic impact, for papers by Anthony J. Hatswell Breakdown of academic impact, for papers by Jonathan Tosh Breakdown of academic impact, for papers by Ágnes Benedict
Rankless by CCL
2026